Cabaletta Bio (CABA) Change in Accured Expenses (2018 - 2025)
Cabaletta Bio's quarterly Change in Accured Expenses came in at $3.1 million in Q4 2025, up 631.88% year-on-year from $417144.0 in Q4 2024, and up 32.05% quarter-over-quarter from $2.3 million in Q3 2025.
Cabaletta Bio has reported Change in Accured Expenses for 8 years, with the latest figure at $3.1 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses rose 631.88% year-over-year to $3.1 million; the trailing twelve-month figure through Dec 2025 stood at $7.4 million (up 88.29% YoY), and the FY2025 full-year result was $7.4 million, up 88.29% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at $3.1 million, up from $2.3 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $6.4 million in Q3 2024, with the low at -$3.5 million in Q1 2025.
- Average Change in Accured Expenses over 5 years is $764200.0, with a median of $798500.0 recorded in 2023.
- Year-over-year, Change in Accured Expenses sank 144.1% in 2022 and jumped 878.15% in 2024.
- Tracing CABA's Change in Accured Expenses over 5 years: stood at $1.7 million in 2021, then plunged by 77.18% to $395000.0 in 2022, then jumped by 674.94% to $3.1 million in 2023, then slumped by 118.75% to -$574000.0 in 2024, then jumped by 631.88% to $3.1 million in 2025.
- The last three Change in Accured Expenses figures came in at $3.1 million (Q4 2025), $2.3 million (Q3 2025), and $5.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.05 Mn |
| Dec 31, 2025 | 3.05 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 5.61 Mn |
| Jun 30, 2025 | 5.61 Mn |
| Mar 31, 2025 | -3.54 Mn |
| Mar 31, 2025 | -3.54 Mn |
| Dec 31, 2024 | -574,000.00 |
| Dec 31, 2024 | -574,000.00 |
| Sep 30, 2024 | 6.45 Mn |
| Sep 30, 2024 | 6.45 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | -3.48 Mn |
| Mar 31, 2024 | -3.48 Mn |
| Dec 31, 2023 | 3.06 Mn |
| Dec 31, 2023 | 3.06 Mn |
| Sep 30, 2023 | 659,000.00 |
| Sep 30, 2023 | 659,000.00 |
| Jun 30, 2023 | 938,000.00 |
| Jun 30, 2023 | 938,000.00 |
| Mar 31, 2023 | -1.68 Mn |
| Mar 31, 2023 | -1.68 Mn |
| Dec 31, 2022 | 395,000.00 |
| Dec 31, 2022 | 395,000.00 |
| Sep 30, 2022 | 432,000.00 |
| Sep 30, 2022 | 432,000.00 |
| Jun 30, 2022 | 1.01 Mn |
| Jun 30, 2022 | 1.01 Mn |
| Mar 31, 2022 | -3.02 Mn |
| Mar 31, 2022 | -3.02 Mn |
| Dec 31, 2021 | 1.73 Mn |
| Dec 31, 2021 | 1.73 Mn |
| Sep 30, 2021 | 1.09 Mn |
| Sep 30, 2021 | 1.09 Mn |
| Jun 30, 2021 | 530,000.00 |
| Jun 30, 2021 | 530,000.00 |
| Mar 31, 2021 | -1.24 Mn |
| Mar 31, 2021 | -1.24 Mn |
| Dec 31, 2020 | 626,000.00 |
| Dec 31, 2020 | 626,000.00 |
| Sep 30, 2020 | 1.04 Mn |
| Sep 30, 2020 | 1.04 Mn |
| Jun 30, 2020 | 1.01 Mn |
| Jun 30, 2020 | 1.01 Mn |
| Mar 31, 2020 | -797,000.00 |
| Mar 31, 2020 | -797,000.00 |
| Dec 31, 2019 | 787,000.00 |
| Dec 31, 2019 | 787,000.00 |
| Sep 30, 2019 | 130,000.00 |
| Sep 30, 2019 | 130,000.00 |
| Jun 30, 2019 | 452,000.00 |
| Jun 30, 2019 | 452,000.00 |
| Mar 31, 2019 | 352,000.00 |
| Mar 31, 2019 | 352,000.00 |
| Dec 31, 2018 | 100,000.00 |
| Dec 31, 2018 | 100,000.00 |